CDC and FDA Expedite the Availability of Additional Doses of New RSV Immunization for Infants
Image
Description
Today, CDC announced the release of more than 77,000 additional doses of Beyfortus(TM) (nirsevimab-alip (100 mg), a long-acting monoclonal antibody designed to protect infants against severe respiratory syncytial virus (RSV) disease.